LightPath Technologies, Inc. (LPTH) Stock Price & How to Invest

LightPath Technologies designs and manufactures precision optics, with a specialty in the infrared. Its historical business was molded aspheric lenses and infrared components built from proprietary BlackDiamond chalcogenide glass, sold to camera makers, industrial customers and defence primes from plants in Orlando, Latvia and China. Three acquisitions changed what the company sells: Visimid brought embedded thermal camera engineering, G5 Infrared (closed February 2025) brought high-performance cooled infrared camera systems with existing programs of record, and the Amorphous Materials asset purchase in January 2026 added chalcogenide glass melting capacity for large-diameter optics. The result is a vertically integrated supplier that owns the glass, the lens, the assembly and, increasingly, the finished camera, which is why assemblies and modules grew to ~$8.4M of the ~$19.1M reported in fiscal third-quarter 2026 revenue.

What re-rated the stock is the combination of that mix shift with a supply chain problem elsewhere. China controls most of the world's germanium, the traditional infrared lens material, and its export licensing regime has pushed Western defence programmes to look for substitutes. LightPath is exclusively licensed by the US Department of Defense to manufacture BDNL-4 as a germanium alternative, and G5 has begun producing germanium-free camera variants using BlackDiamond glass. Orders followed: an ~$18.2M infrared camera award, ~$13M of follow-on counter-drone optical assembly orders for delivery into 2027, and several smaller defence qualification orders. Backlog reached ~$110.6M at March 31, 2026, up ~196% from ~$37.4M nine months earlier. The company is still unprofitable on a GAAP basis and funded that growth with equity, so the investment question is less about whether demand is real and more about the price now attached to it.

Valuation is the first-order risk: at roughly $950M to $1.0B of market value against ~$63M of trailing twelve-month revenue, the stock trades near 15x to 16x sales while still reporting a trailing net loss of about $23M, so the price already discounts several years of backlog conversion going right. Dilution history is the second: common shares outstanding went from ~42.9M at June 30, 2025 to ~61.2M at March 31, 2026, and pro forma for the June 2026 placement and Series G preferred conversions the count is closer to ~70M, meaning existing holders funded the growth by giving up roughly a third of the company inside a year. Execution risk is real and concentrated, because three acquisitions in three years must be integrated while a cooled camera family is redesigned onto new glass, and a slipped qualification pushes revenue by quarters rather than weeks. Customer and programme concentration cuts both ways, since single orders of $13M to $18M are large relative to the revenue base and their delivery schedules extend into 2027. Worth noting factually: Purcell and Lefkowitz issued a shareholder alert in September 2023 saying it was investigating potential breaches of fiduciary duty by the board, which is a law-firm press release rather than a filed complaint, and no securities-fraud class action against the company appears on a docket. Manufacturing exposure in China and Latvia adds tariff, export-control and geopolitical friction to a business whose main selling point is supply chain independence from China.

5 analysts publish price targets on LPTH, averaging $15.78 against a $15.17 price as of August 2026, or +4.0%. The published targets run from $15.00 to $17.00, a narrow spread, and the ratings split 5 buy, 0 hold, 0 sell. Over the last six months there has been 1 raise and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full LPTH forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on LightPath Technologies, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Germanium substitution is a materials moat, not just a product line. China's germanium export licensing has made the standard infrared lens material scarce and expensive for US and allied defence buyers, with ingot prices setting records after the restrictions took effect. The most optimistic published target, $17.00, assumes this works close to its best case.

The case against. Valuation is the first-order risk: at roughly $950M to $1.0B of market value against ~$63M of trailing twelve-month revenue, the stock trades near 15x to 16x sales while still reporting a trailing net loss of about $23M, so the price already discounts several years of backlog conversion going right. The most pessimistic target, $15.00, is roughly what LPTH is worth if this bites instead.

Read the full bull and bear case on LPTH, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see LightPath Technologies, Inc.'s investor relations page or your broker.

• Revenue (TTM): ~$63M, up ~87% year over year
• Latest quarter (fiscal Q3 2026, ended March 31, 2026): revenue ~$19.1M, up ~109%; gross margin ~36%
• Order backlog: ~$110.6M at March 31, 2026, up ~196% from ~$37.4M at June 30, 2025
• Profitability: adjusted EBITDA ~$1.1M in fiscal Q3 2026 (third straight positive quarter); TTM net loss ~$23M
• Cash and debt: ~$55.2M cash at March 31, 2026, long-term debt near nil, plus ~$47.0M net from the June 2026 placement
• Market value and multiple: ~$950M to ~$1.0B, roughly 15x to 16x TTM sales; 52-week range ~$3.36 to ~$18.94

LightPath runs a June fiscal year, so as of August 2026 the most recent reported period is fiscal third-quarter 2026, ended March 31, 2026, and fiscal fourth-quarter plus full-year fiscal 2026 results have not yet been published. Trailing twelve-month revenue of ~$63M therefore spans fiscal fourth-quarter 2025 (~$12.2M) plus the first nine months of fiscal 2026 (~$50.6M), against full fiscal 2025 revenue of ~$37.2M. Management has described a three-pillar strategy targeting in excess of $300M of annual revenue within five years, which is an ambition rather than guidance and sits far above both current revenue and current backlog.

Other names that sit close to LPTH: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get LPTH exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so LPTH sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where LPTH fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

LightPath now has genuine defence backlog, real cameras and a germanium-free materials advantage behind its re-rating, and it also has a mid-teens sales multiple, GAAP losses and a heavily expanded share count sitting on the other side of the ledger.

Whether LPTH is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is LPTH a buy or a sell?, and where the stock could go from here in the LPTH stock forecast.

For income investors, whether LPTH pays a dividend and how the payout looks is covered in does LPTH pay a dividend? And to weigh LPTH against a peer, read the full side-by-side comparisons: LPTH vs TDY and LPTH vs DRS.